Human immunodeficiency virus type 1 neutralization by plasma from B or F genotype infected individuals

Memorias do Instituto Oswaldo Cruz

Volumn 100, Issue 1, 2005, Pages 85-89

  Bongertz, V ^a   Teixeira, S L M ^a   Grinztejn, B ^b   Pilotto, J H ^b   Veloso, V G ^b   Morgado, M G ^a   Bastos, F I ^c   Ouverney, E P ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b Instituto de pesquisa Clinica Evandro   (Brazil)

^c Fiocruz Av Brasil 4365 21045 900   (Brazil)

Author keywords

Brazil; Genotype; Human immunodeficiency virus type 1; Neutralization

Indexed keywords

NEUTRALIZING ANTIBODY;

ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN BINDING; BLOOD SAMPLING; CLADISTICS; COMPARATIVE STUDY; CONFERENCE PAPER; CONTROLLED STUDY; CROSS REACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; INFECTION SENSITIVITY; MAJOR CLINICAL STUDY; VIRUS ISOLATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 15244349135     PISSN: 00740276     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0074-02762005000100016     Document Type: Conference Paper

References (37)

1. Baba TW, Liska V, Hofmann-Lehmann R, Vlasak J, Xu W, Ayehunie S, Cavacini LA, Posner MR, Katinger H, Stiegler G, Bernacky BJ, Rizvi TA, Schmidt R, Hill LR, Keeling ME, Lu Y, Wright JE, Chou TC, Ruprecht RM 2000. Human neutralizing monoclonal antibodies of the IgG1 sub-type protect against mucosal simian-human immunodeficiency virus infection. Nat Med 6: 200-206
2. Bongertz V, Costa CI, Veloso VG, Grinsztejn B, João Filho EC, Calvet G, Pilotto JH, Guimarães ML, Morgado MG 2001. Vertical HIV-1 transmission: importance of neutralizing antibody titer and specificity. Scand J Immunol 53: 302-309.
3. Bongertz V, Costa CI, Veloso VG, Grinsztejn B, João Filho EC, Calvet G, Pilotto JH, Guimarães ML, Morgado MG 2002. Neutralization titers and Vertical HIV-1 transmission. Scand J Immunol 56: 642-644.
4. Bongertz V, Guimaräes ML, Soares-da-Costa MFG, Veloso-dos-Santos VG, The HEC/Fiocruz AIDS Clin Res Group, Bastos FI, Telles PR, Morgado MG 1999. Anti-HIV-1 seroreactivity in distinct transmission risk groups. J Clin Virol 12: 27-36.
5. Bongertz V, Ouverney EP, Teixeira SLM, C Silva-de-Jesus, MA Hacker, MG Morgado, FI Bastos, The Brazilian Network for HIV Isolation and Characterization 2003. Higher anti-HIV-1 antibody titers in injection drug users compared to sexually infected individuals. Mem Inst Oswaldo Cruz 98: 209-212.
6. Bradac J, Ho D 1992. Summary of the Antigenic Variation Working Group. AIDS Res Hum Retroviruses 8: 1419-1421.
7. Cheingsong-Popov R, Lister S, Callow D, Kaleebu P, Beddows S, Weber J 1994. Serotyping HIV type 1 by antibody binding to the V3 loop: relationship to viral genotype. WHO Network for HIV Isolation and Characterization. AIDS Res Hum Retroviruses 10: 1379-1386.
8. Delwart EL, Shpear EG, Louwagie J, Mc Cutchan FE, Grez M, Ruebsamen-Waigmann H, Mullins J 1993. Genetic relationships determined by a DNA heteroduplex motility assay: Analysis of HIV-1 env genes. Science 262: 1257-1261
9. Dianzani F, Antonelli G, Riva E, Turriziani O, Antonelli L, Tyring S, Carrasco DA, Lee H, Nguyen D, Pan J, Poast J, Cloyd M, Baron S 2002. Is human immunodeficiency virus RNA load composed of neutralized immune complexes? J Infect Dis 185: 1051-1054.
10. Ferrantelli F, Ruprecht RM 2002. Neutralizing antibodies against HIV - Back in the major leagues? Curr Opin Immunol 14: 495-502.
11. Ferrantelli F, Kitabwalla M, Rasmussen RA, Cao C, Chou TC, Katinger H, Stiegler G, Cavacini LA, Bai Y, Cotropia J, Ugen KE, Ruprecht RM 2004. Potent cross-group neutralization of primary human immunodeficiency virus isolates with monoclonal antibodies-implications for acquired immunodeficiency syndrome vaccine. J Infect Dis 189: 71-74.
12. Guimarães ML, dos Santos Moreira A, Loureiro R, Galvão-Castro B, Morgado MG; Brazilian Network for HIV Isolation and Characterization 2002. High frequency of recombinant genomes in HIV type 1 samples from Brazilian southeastern and southern regions. AIDS Res Hum Retroviruses 18: 1261-1269.
13. Ho DD, Rota TR, Schooley RT, Kaplan JC, Allan JD, Groopman JE, Resnick L, Felsenstein D, Andrews CA, Hirsch MS 1985. Isolation of HTLV-III from cerebrospinal fluid and neural tissues of patients with neurologic syndromes related to the acquired immunodeficiency syndrome. N Engl J Med 313: 1493-1497.
14. Hofmann-Lehmann R, Rasmussen RA, Vlasak J, Smith BA, Baba TW, Liska V, Montefiori DC, McClure HM, Anderson DC, Bernacky BJ, Rizvi TA, Schmidt R, Hill LR, Keeling ME, Katinger H, Stiegler G, Posner MR, Cavacini LA, Chou TC, Ruprecht RM 2001. Passive immunization against oral AIDS virus transmission: an approach to prevent mother-to-infant HIV-1 transmission? J Med Primatol 30: 190-196.
15. Igarashi T, Brown C, Azadegan A, Haigwood N, Dimitrov D, Martin MA, Shibata R 1999. Human immunodeficiency virus type 1 neutralizing antibodies accelerate clearance of cell-free virions from blood plasma. Nat Med 5: 211-216.
16. Kostrikis LG, Cao Y, Ngai H, Moore JP, Ho DD 1996. Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement. J Virol 70: 445-458.
17. Mascola JR 2002. Passive transfer studies to elucidate the role of antibody-mediated protection against HIV-1. Vaccine 20: 1922-1925.
18. Mascola JR, Lewis MG, VanCott TC, Stiegler G, Katinger H, Seaman M, Beaudry K, Barouch DH, Korioth-Schmitz B, Krivulka G, Sambor A, Welcher B, Douek DC, Montefiori DC, Shiver JW, Poignard P, Burton DR, Letvin NL 2003. Cellular immunity elicited by human immunodeficiency virus type 1/simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies. J Virol 77: 10348-10356.
19. Mascola JR, Louwagie J, McCutchan FE, Fischer CL, Hegerich PA, Wagner KF, Fowler AK, McNeil JG, Burke DS 1994. Two antigenically distinct subtypes of human immunodeficiency virus type 1: viral genotype predicts neutralization serotype. J Infect Dis 169: 48-54.
20. Mascola JR, Louder MK, Surman SR, Vancott TC, Yu XF, Bradac J, Porter KR, Nelson KE, Girard M, McNeil JG, McCutchan FE, Birx DL, Burke DS 1996. Human immunodeficiency virus type 1 neutralizing antibody serotyping using serum pools and an infectivity reduction assay. AIDS Res Hum Retroviruses 12: 1319-1328.
21. Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, Hanson CE, Beary H, Hayes D, Frankel SS, Birx DL, Lewis MG 2000. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 6: 207-210.
22. McKnight A, Clapham PR, Goudsmit J, Cheingsong-Popov R, Weber JN, Weiss RA 1992. Development of HIV-1 group-specific neutralizing antibodies after seroconversion. AIDS 6: 799-802.
23. Morgado MG, Guimarães ML, Galvão-Castro B 2002. HIV-1 polymorphism: a challenge for vaccine development - A review. Mem Inst Oswaldo Cruz 97: 143-150.
24. Morgado MG, Guimarães ML, Gripp CBG, Costa CI, Neves Jr I, Veloso VG, Linhares de Carvalho MI, Castello-Branco LR, Bastos FI, Kuiken C, Castilho EA, Galvão-Castro B, Bongertz V, The HEC AIDS Clin Res Group 1998. Molecular epidemiology of HIV in Brazil: high prevalence of B subtype and identification of a HIV-1 subtype D infection in Rio de Janeiro City. J AIDS Human Retrovirol 18: 488-494.
25. Nishimura Y, Igarashi T, Haigwood N, Sadjadpour R, Plishka RJ, Buckler-White A, Shibata R, Martin MA 2002. Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies. J Virol 76: 2123-2130.
26. Parren PW, Marx PA, Hessell AJ, Luckay A, Harouse J, Cheng-Mayer C, Moore JP, Burton DR 2001. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 75: 8340-8347.
27. Pugach P, Kuhmann SE, Taylor J, Marozsan AJ, Snyder A, Ketas T, Wolinsky SM, Korber BT, Moore JP 2004. The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4. Virology 321: 8-22
28. Robert-Guroff M, Brown M, Gallo RC 1985. HTLV-III neutralising antibodies in patients with AIDS and AIDS-related complex. Nature (London) 316: 72-74.
29. Ruprecht RM, Hofmann-Lehmann R, Smith-Franklin BA, Rasmussen RA, Liska V, Vlasak J, Xu W, Baba TW, Chenine AL, Cavacini LA, Posner MR, Katinger H, Stiegler G, Bernacky BJ, Rizvi TA, Schmidt R, Hill LR, Keeling ME, Montefiori DC, McClure HM 2001. Protection of neonatal macaques against experimental SHIV infection by human neutralizing monoclonal antibodies. Transfus Clin Biol 8: 350-358.
30. Vicente AC, Otsuki K, Silva NB, Castilho MC, Barros FS, Pieniazek D, Hu D, Rayfield MA, Bretas G, Tanuri A 2000. The HIV epidemic in the Amazon Basin is driven by prototypic and recombinant HIV-1 subtypes B and F. J Acquir Immune Defic Syndr 23: 327-231.
31. Weber J, Fenyö EM, Beddows S, Kaleebu P, Bjorndal A 1996. Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic sub-type. The WHO Network for HIV Isolation and Characterization. J Virol 70: 7827-7832.
32. Weiss RA, Clapham PR, Cheingsong-Popov R, Dalgleish AG, Came CA, Weller IVD, Tedder RS 1985. Neutralisation of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients. Nature (London) 316: 69-72.
33. Xiao Y, Dong X, Chen YH 2002. Neutralizing antibodies mechanism of neutralization and protective activity against HIV-1. Immunol Res 25: 193-200.
34. Xu W, Hofmann-Lehmann R, McClure HM, Ruprecht RM 2002. Passive immunization with human neutralizing monoclonal antibodies: correlates of protective immunity against HIV. Vaccine 20: 1956-1960.
35. Zhang YJ, Hatziioannou T, Zang T, Braaten D, Luban J, Goff SP, Bieniasz PD 2002. Envelope-dependent, cyclophilin-independent effects of glycosaminoglycans on human immunodeficiency virus type 1 attachment and infection. J Virol 76: 644-655.
36. Zolla-Pazner S 2004. Identifying epitopes of HIV-1 that induce protective antibodies. Nat Rev Immunol 4: 199-210.
37. Zolla-Pazner S, Gorny MK, Nyambi PN, VanCott TC, Nadas A 1999. Immunotyping of human immunodeficiency virus type 1 (HIV): an approach to immunologic classification of HIV. J Virol 73: 4042-4051.